Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Preclinical data support a novel combination of MB-101 (IL13Ra2-targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) to optimize clinical results FDA previously granted Orphan Drug ...

The group hypothesized that teclistamab would have the same effect: its mechanism of action should stimulate "CD3-positive T-cell activation and the subsequent destruction of target cells," in ...

APVO455 is a preclinical Nectin-4 x CD3 bispecific T-cell engager designed for tumors such ... activation in the periphery and do so only in the presence of Nectin-4 positive tumor cells, ...

We present a case of peripheral T-cell lymphoma co-expressing CD3 and CD20, as well as demonstrating T-cell receptor gene rearrangement, in a patient who had been diagnosed with nodular sclerosis ...

Explore how the ratio of pd-1+ treg to ctl and the presence of tertiary lymphoid structures can influence treatment outcomes ...

ABP-102/CT-P72 an investigational HER2 x CD3 bispecific T-cell engager designed to selectively target HER2-overexpressing tumor cells while reducing activity in HER2-low expressing normal tissues.

Forte Biosciences (FBRX) announced data from a Phase 1b trial in celiac disease for lead program FB102. The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized. Subjects ...

APVO455 is a preclinical Nectin-4 x CD3 bispecific T-cell engager designed for tumors such as bladder, breast, NSCLC, and head and neck cancers, where Nectin-4 is highly expressed.

Unlike other approaches that restrict activity to acidic tumor environments or rely on activated T-cells, APVO455 is designed to avoid binding to or triggering T-cell activation in the periphery and ...